Clinical Trial Update: A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial evaluating the combination of fianlimab and cemiplimab with or without ipilimumab, or ipilimumab plus nivolumab, as first-line therap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Cemiplimab (cemiplimab)
• Fianlimab (fianlimab)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Brian Rini | Conditions: Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC) | Phase 2 | Status: RECRUITING